Tien Liang BioTech Co (ROCO:4127) Cyclically Adjusted FCF per Share: NT$-0.27 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4127 Tien Liang BioTech Co Ltd ROCO:4127
30 GF Score
Price NT$77.20
GF Value NT$45.56
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Tien Liang BioTech Co Cyclically Adjusted FCF per Share?

Tien Liang BioTech Co ROCO:4127 +3.62% 30 Cyclically Adjusted FCF per Share is NT$-0.27 as of Mar. 2026. GuruFocus rates ROCO:4127 with a GF Score™ of 30/100 and a GF Value™ of NT$45.56 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Tien Liang BioTech Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was NT$0.222. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$-0.27 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Tien Liang BioTech Co was -41.50% per year. The lowest was -41.50% per year. And the median was -41.50% per year.

As of today (2026-08-04), Tien Liang BioTech Co's current stock price is NT$77.20. Tien Liang BioTech Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was NT$-0.27. Tien Liang BioTech Co's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Tien Liang BioTech Co was 1480.00. The lowest was 24.61. And the median was 66.73.


Tien Liang BioTech Co  (ROCO:4127) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Tien Liang BioTech Co was 1480.00. The lowest was 24.61. And the median was 66.73.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Tien Liang BioTech Co Cyclically Adjusted FCF per Share Related Terms


Tien Liang BioTech Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Tien Liang BioTech Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tien Liang BioTech Co Cyclically Adjusted FCF per Share Chart

Tien Liang BioTech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.06 -0.11 -0.13 -0.32

Tien Liang BioTech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.31 -0.25 -0.32 -0.27

ROCO:4127 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tien Liang BioTech Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tien Liang BioTech Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tien Liang BioTech Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Tien Liang BioTech Co's Cyclically Adjusted Price-to-FCF falls into.


ROCO:4127
30GF Score
Tien Liang BioTech Co Ltd ROCO:4127
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tien Liang BioTech Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tien Liang BioTech Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.222/330.2130*330.2130
=0.222

Current CPI (Mar. 2026) = 330.2130.

Tien Liang BioTech Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.200 241.018 -0.274
201609 -0.304 241.428 -0.416
201612 -0.495 241.432 -0.677
201703 -0.335 243.801 -0.454
201706 -0.150 244.955 -0.202
201709 -1.102 246.819 -1.474
201712 -0.920 246.524 -1.232
201803 0.105 249.554 0.139
201806 -0.291 251.989 -0.381
201809 -0.250 252.439 -0.327
201812 -0.117 251.233 -0.154
201903 -0.070 254.202 -0.091
201906 -0.335 256.143 -0.432
201909 -0.042 256.759 -0.054
201912 -0.503 256.974 -0.646
202003 -0.337 258.115 -0.431
202006 -0.098 257.797 -0.126
202009 0.029 260.280 0.037
202012 0.139 260.474 0.176
202103 -0.007 264.877 -0.009
202106 -0.201 271.696 -0.244
202109 0.422 274.310 0.508
202112 0.772 278.802 0.914
202203 0.494 287.504 0.567
202206 -0.263 296.311 -0.293
202209 -0.229 296.808 -0.255
202212 0.452 296.797 0.503
202303 -0.364 301.836 -0.398
202306 0.740 305.109 0.801
202309 0.429 307.789 0.460
202312 0.584 306.746 0.629
202403 0.623 312.332 0.659
202406 -0.364 314.175 -0.383
202409 0.108 315.301 0.113
202412 0.585 315.605 0.612
202503 0.493 319.799 0.509
202506 -0.269 322.561 -0.275
202509 0.143 324.800 0.145
202512 -0.451 324.054 -0.460
202603 0.222 330.213 0.222

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$-0.27 mean?
Tien Liang BioTech Co (ROCO:4127) has a Cyclically Adjusted FCF per Share of NT$-0.27 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Tien Liang BioTech Co and its competitors.
Is Tien Liang BioTech Co's Cyclically Adjusted FCF per Share too high?
Tien Liang BioTech Co's current Cyclically Adjusted FCF per Share is NT$-0.27. Overall, Tien Liang BioTech Co has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tien Liang BioTech Co's Cyclically Adjusted FCF per Share compare to ZTS?
Tien Liang BioTech Co's Cyclically Adjusted FCF per Share of NT$-0.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Tien Liang BioTech Co and its competitors. Tien Liang BioTech Co's current Cyclically Adjusted FCF per Share is NT$-0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tien Liang BioTech Co stock overvalued right now?
Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$45.56, compared to a current price of NT$77.20 — trading 69.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$-0.27. Tien Liang BioTech Co's overall GF Score™ is 30/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current Cyclically Adjusted FCF per Share is NT$-0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?

Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued. The current stock price of NT$77.20 is trading 69.4% above its estimated GF Value™ of NT$45.56. GuruFocus considers Tien Liang BioTech Co to be Significantly Overvalued.

Key valuation signals for ROCO:4127:

  • Cyclically Adjusted FCF per Share: NT$-0.27
  • GF Value™: NT$45.56 vs. price of NT$77.20 (69.4% above fair value)
  • GF Score™: 30/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tien Liang BioTech Co Business Description

Address No. 147, Section 1, Datong Road, 9th Floor, Xizhi District, New Taipei City, TWN
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.
30GF Score

Get the complete analysis for ROCO:4127

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$77.20
Price
NT$45.56
GF Value